Navigation Links
Takeda to Acquire Nycomed
Date:5/18/2011

xpectations. We are proud to have contributed to Nycomed's development into a world-class pharmaceutical company with a strong market position and product pipeline. I feel confident that Takeda will be able to further build upon Nycomed's potential and create an even stronger company with a global market presence," said Kristoffer Melinder, Managing Partner of NC Advisory AB, advisor to the Nordic Capital funds.

1.  Expected benefits

  • Strong fit with Takeda’s sustainable growth strategy
  • Strengthens pan-European platform
  • Leverages Nycomed’s emerging markets strength to drive growth
  • Allows Takeda to maximize the value of its portfolio supported by enhanced development expertise and commercialization capability in Europe and emerging markets
  • Provides a significant growth driver with roflumilast (Daxas® tradename in Europe)
  • Immediate financial contribution(*)
  • More than 30% increase of annual revenue
  • More than 40% increase of operating income (excluding special factors derived from business acquisition)
  • More than 30% increase of EPS (excluding special factors derived from business acquisition)

  • (*) Comparison with the original outlook of fiscal 2013 in 2011-2013 Mid-Range Plan, announced on May 11, 2011

  • Complementary cultures and diverse talent pool

  • 2.  Acquisition summary (1)

    Acquiring company: Takeda Pharmaceutical Company Limited(2)

    Shareholders of Nycomed include Nordic Capital Funds V and VI, DLJ Merchant Banking Partners (a Credit Suisse affiliate), Coller International Partners IV and V, and Avista Capital Partners, Nycomed’s management and employees team(3)

    Number of outstanding shares: 13,778,110 shares (as of December 31, 2010)(4)

    Payment: Cash (Takeda will finance part of the transaction through a loan for about 600 to 700 billion yen)(5)

    Acquisition amount: &
    '/>"/>

    SOURCE Takeda Pharmaceutical Company Limited
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
    2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
    3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
    4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
    5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
    6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
    7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
    8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
    9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
    10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
    11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
    (Date:9/1/2015)... -- Sleep Specialists, LLC a medical device company ... Solutions, a leader in digital health and chronic ... and cost reduction program for patients with Obstructive ... chronic medical condition characterized by periods of interrupted ... risk for cardiovascular disease, hypertension, stroke, congestive heart ...
    (Date:9/1/2015)... RIVER, Mass. , Sept. 1, 2015   ... an additional 120,000 square feet in Olive Branch, ... Olive Branch facility has added the ... warehousing space. "This expansion gives us the ... Karl Neuberger , President of Millstone MS. "Two and a ...
    Breaking Medicine Technology:Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Millstone Medical Outsourcing Announces Olive Branch Expansion 2
    (Date:9/1/2015)... ... 2015 , ... According to a study published August 25th in ... in a three year study about weight loss and diabetes were far more likely ... loss surgery at the onset of the trial. In fact, the participants in the ...
    (Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted ... ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College in Brooklyn ... some of whom work for Calvary, and two junior counselors who were campers themselves ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... of the American Society for Dermatologic Surgery, according to a new survey that ... Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical ...
    (Date:9/1/2015)... TX (PRWEB) , ... September 01, 2015 , ... ... that it is now offering the MonaLisa Touch® , an innovative vaginal ... The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition ...
    (Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding members, Inmar ... inception more than 35 years ago. A pilot program begun by the company in ... not just those intent on pursuing careers in these fields. The program is now ...
    Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2
    ... 18 (HealthDay News) -- Flu vaccination levels among U.S. ... are still below the 2020 national health objectives, a ... for Disease Control and Prevention also found that too ... care personnel should get an annual flu vaccination, according ...
    ... tumors aren,t uniform: they are more like complex societies, ... playing different roles. Understanding this "social structure" of tumors ... different cell types may be sensitive to different drugs. ... society, in which all cancer cells descend from special ...
    ... Fighting Drug, Vemurafenib Powerful X-Rays Enable ... Life-Threatening Diseases WASHINGTON, DC Powerful X-ray ... (DOE,s) national laboratories is revealing new insights into ... and, most recently, enabled the discovery of a ...
    ... , THURSDAY, Aug. 18 (HealthDay News) -- Many doctors continue ... guidelines say some women can wait much longer between tests. ... Katherine Roland, a behavioral scientist at the U.S. Centers for ... with the guidelines," Roland said. The downsides of too-frequent ...
    ... For the first time, researchers at Seattle Cancer ... serial positron emission tomography (PET) scans, using a ... of estrogen-blocking and estrogen-depleting therapy in patients with ... are published online in Clinical Cancer Research ...
    ... , WEDNESDAY, Aug. 17 (HealthDay News) -- A newer ... consciousness while under anesthesia is no better than conventional ... new research shows. In fact, the newer system ... is known as bispectral index (BIS) monitoring -- actually ...
    Cached Medicine News:Health News:Flu Shot Rates Low for Health Workers, Moms-to-Be: CDC 2Health News:Cancer stem cells made, not born 2Health News:Cancer stem cells made, not born 3Health News:DOE laboratories help develop promising new cancer fighting drug, vemurafenib 2Health News:Annual Pap Tests Often Ordered But Unneeded: Study 2Health News:Annual Pap Tests Often Ordered But Unneeded: Study 3Health News:PET scans confirm effectiveness of estrogen-blocking drugs in breast cancer patients 2Health News:Method to Detect When Patients Wake During Surgery Fails to Impress 2Health News:Method to Detect When Patients Wake During Surgery Fails to Impress 3
    ... HT is designed for extended temperatures. ... ideal for applications such as DNA ... Incubator/Shaker HT is available as a ... three microplates. Iems Incubator/Shaker HT including ...
    ... are designed to give reliable performance for all ... on/off button, power supply socket and fuse holder ... unit. The speed knob is located on the ... from a minimum 950 rpm to a maximum ...
    ... only four-color, automated benchtop flow cytometry system ... sorting. Designed specifically to support a wide ... software instrument control, auto-sample loading, and push-button ... FACSCalibur is fully modular so it can ...
    ... cytometer for any kind of cell ... CyFlow SL analyzes forward and side ... to 3 fluorescence channels. Data acquisition, ... with a PC or laptop employing ...
    Medicine Products: